<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0404233476
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Carcivor 250 mg per 5 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FULVESTRANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1237.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Laboratories Farmalan SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Laboratories Farmalan SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CARCIVOR contains the active substance fulvestrant, which belongs to the group of estrogen blockers. Estrogens, a type of female sex hormones, can in some cases be involved in the growth of breast cancer.</p><p>&nbsp;</p><p>CARCIVOR is used either:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alone, to treat postmenopausal women with a type of breast cancer called estrogen receptor positive breast cancer that is locally advanced or has spread to other parts of the body (metastatic), or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, that is locally advanced or has spread to other parts of the body (metastatic). Women who have not reached menopause will also be treated with a medicine called a luteinizing hormone releasing hormone (LHRH) agonist.</p><p>&nbsp;</p><p>When CARCIVOR is given in combination with palbociclib, it is important that you also read the package leaflet for palbociclib. If you have any questions about palbociclib, please ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should NOT be given </strong><strong>CARCIVOR</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before being treated with CARCIVOR if any of these apply to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney or liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low numbers of platelets (which help blood clotting) or bleeding disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Previous problems with blood clots</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Osteoporosis (loss of bone density)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcoholism.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>CARCIVOR is not for use in children and adolescents under 18 years.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>CARCIVOR</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, you should tell your doctor if you are taking anticoagulants (medicines to prevent blood clots).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>You must not be given CARCIVOR if you are pregnant. Women who are able to become pregnant should use effective contraception while being treated with CARCIVOR and for 2 years after your last dose.</p><p>&nbsp;</p><p>You must not breast-feed while on treatment with CARCIVOR.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>CARCIVOR is not expected to affect your ability to drive or use machines. However, if you feel tired after treatment do not drive or use machines.</p><p>&nbsp;</p><p><strong>CARCIVOR contains 500 mg of alcohol (ethanol) </strong>in each injection which is equivalent to 100 mg/ ml (10% w/v). The amount in each injection of this medicine is equivalent to 13 ml beer or 5 ml wine.</p><p>&nbsp;</p><p>The amount of alcohol in this medicine is not likely to have an effect in adults and adolescents.</p><p>The alcohol in this medicine may alter the effects of other medicines. Talk to your doctor of pharmacist if you are taking other medicines.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>If you are adicted to alcohol, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>CARCIVOR contains 500 mg benzyl alcohol per injection, </strong>equivalent to 100 mg/ml.</p><p>Benzyl alcohol may cause allergic reactions.</p><p>&nbsp;</p><p><strong>CARCIVOR contains 750 mg benzyl benzoate per injection</strong>, equivalent to 150 mg /ml.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor or nurse will give you CARCIVOR as a slow intramuscular injection, one into each of your buttocks.</p><p>&nbsp;</p><p>The recommended dose is 500 mg fulvestrant (two 250 mg/5 ml injections) given once a month, with an additional 500 mg dose given 2 weeks after the initial dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects </strong></p><p><strong>&nbsp;</strong></p><p><strong>You may need immediate medical treatment</strong> <strong>if you experience any of the following side effects </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat that may be signs of anaphylactic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolism (increased risk of blood clots)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure</p><p>&nbsp;</p><p><strong>Tell your doctor, pharmacist, or nurse if you notice any of the following side effects: </strong></p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions, such as pain and/or inflammation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal levels of liver enzymes (in blood tests)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness, tiredness*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint and musculoskeletal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flushes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat</p><p>&nbsp;</p><p><strong>All other side effects:</strong></p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)<strong> </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, diarrhoea, or loss of appetite*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of bilirubin (bile pigment produced by the liver)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolism (increased risk of blood clots)*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased levels of platelets (thrombocytopenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vaginal bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower back pain irradiating to the leg on one side (sciatica)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden weakness, numbness, tingling, or loss of movement in your leg, especially if only on one side of your body, sudden problems with walking or balance (peripheral neuropathy).</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thick, whitish vaginal discharge and candidiasis (infection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising and bleeding at the site of injection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of gamma-GT, a liver enzyme seen in a blood test</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling and pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reactions.</p><p>&nbsp;</p><p>* Includes side effects for which the exact role of CARCIVOR cannot be assessed due to the underlying disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton or syringe labels after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store and transport refrigerated (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature excursions outside 2&deg;C to 8&deg;C should be limited. This includes avoiding storage at temperatures exceeding 30&deg;C, and not exceeding a 28 day period where the average storage temperature for the product is below 25&deg;C (but above 2&deg;C to 8&deg;C). After temperature excursions, the product should be returned immediately to the recommended storage conditions (store and transport in a refrigerator 2&deg;C to 8&deg;C). Temperature excursions have a cumulative effect on the product quality and the 28 day time period must not be exceeded over the duration of the shelf life of CARCIVOR. Exposure to temperatures below 2&deg;C will not damage the product providing it is not stored below -20&deg;C.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the pre-filled syringe in the original package, in order to protect from light.</p><p>&nbsp;</p><p>Your healthcare professional will be responsible for the correct storage, use and disposal of CARCIVOR</p><p>&nbsp;</p><p>This medicine may pose a risk to the aquatic environment. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>&nbsp;</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is fulvestrant. Total quantity per total volume 250 mg per 5 ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amount in unit volume 50 mg/ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients (excipients) are ethanol (96 percent), benzyl alcohol (E1519), benzyl benzoate and castor oil refined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CARCIVOR is a clear, colourless to yellow, viscous solution in a pre-filled syringe, containing 5 ml solution for injection. Two syringes must be administered to receive the 500 mg recommended monthly dose. 

CARCIVOR has 3 pack presentations, a pack containing 1 glass pre-filled syringe, a pack containing 2 glass pre-filled syringes and a pack containing 6 glass pre-filled syringes. One, two or six safety needles (BD SafetyGlide) for connection to each barrel are also provided. 

	Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>Laboratorios Farmalan SA</p><p>Calle La Vallina, s n Edificio 2&nbsp;</p><p>Poligono&nbsp;Industrial Navatejera,</p><p>24193&nbsp;Villaquilambre Leon, Spain</p><p><br />&nbsp;</p><p><strong>Marketing Authorization Holder:</strong></p><p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كارسيڨور على المادة الفعالة فولفيسترانت، التي تنتمي إلى مجموعة حاصرات هرمون الاستروجين. يمكن للإستروجين، وهو نوع من الهرمونات الجنسية الأنثوية، أن يشارك في بعض الحالات في نمو سرطان الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم استخدام كارسيڨور إما:</p><p dir="RTL">- وحده، لعلاج النساء بعد انقطاع الطمث المصابات بنوع من سرطان الثدي يسمى سرطان الثدي الإيجابي لمستقبلات هرمون الاستروجين والذي يكون متقدمًا محليًا أو انتشر إلى أجزاء أخرى من الجسم (المنتشر)، أو</p><p dir="RTL">- بالاشتراك مع بالبوسيكليب لعلاج النساء المصابات بنوع من سرطان الثدي يسمى سرطان الثدي إيجابي مستقبلات الهرمون وعامل نمو البشرة البشري 2 سلبي، والذي يكون متقدمًا محليًا أو انتشر إلى أجزاء أخرى من الجسم (المنتشر). سيتم أيضًا علاج النساء اللواتي لم يصلن إلى سن اليأس بدواء يسمى ناهض الهرمون المطلق للهرمون الملوتن (LHRH).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاء كارسيڨور مع بالبوسيكليب، من المهم أن تقرأ أيضًا نشرة العبوة الخاصة بـ بالبوسيكليب. إذا كان لديك أي أسئلة حول بالبوسيكليب، من فضلك اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول</strong>&nbsp;<strong>كارسيڨور:</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه فولفيسترانت أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">- إذا كنت حاملاً أو ترضعين طفلك طبيعياً</p><p dir="RTL">- إذا كنت تعاني من مشاكل خطيرة في الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل علاجك بهذا الدواء إذا انطبق عليك أي مما يلي:</p><p dir="RTL">- مشاكل في الكلى أو الكبد</p><p dir="RTL">- قلة عدد الصفائح الدموية (التي تساعد على تخثر الدم) أو اضطرابات النزيف</p><p dir="RTL">- مشاكل جلطات الدم السابقة</p><p dir="RTL">- هشاشة العظام (فقدان كثافة العظام)</p><p dir="RTL">- إدمان الكحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">كارسيڨور غير مخصص للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وكارسيڨور</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخراً، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، يجب أن تخبر طبيبك إذا كنت تتناول مضادات التخثر (أدوية لمنع تجلط الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يجوز إعطاؤك كارسيڨور إذا كنت حاملاً. يجب على النساء القادرات على الحمل استخدام وسيلة فعالة لمنع الحمل أثناء العلاج باستخدام كارسيڨور ولمدة عامين بعد آخر جرعة.</p><p dir="RTL">لا يجوز إرضاعك لطفلك طبيعياً أثناء العلاج بـ كارسيڨور.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس من المتوقع أن يؤثر كارسيڨور على قدرتك على القيادة أو استخدام الآلات. ومع ذلك، إذا شعرت بالتعب بعد العلاج، فلا تقم بالقيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كارسيڨور 500 ملجم من الكحول (إيثانول) </strong>في كل حقنة تعادل 100 ملجم / مل (10٪ وزن / حجم). الكمية في كل حقنة من هذا الدواء تعادل 13 مل من البيرة أو 5 مل من النبيذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس من المحتمل أن يكون لكمية الكحول في هذا الدواء تأثير على البالغين والمراهقين.</p><p dir="RTL">قد يغير الكحول في هذا الدواء من آثار الأدوية الأخرى. تحدث إلى طبيبك الصيدلي إذا كنت تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك طبيعياً، تحدثي إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مدمنًا على الكحول، تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كارسيڨور على 500 ملجم كحول بنزيل لكل حقنة</strong>، أي ما يعادل 100 ملجم / مل.</p><p dir="RTL">قد يسبب كحول البنزيل ردود فعل تحسسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كارسيڨور على 750 ملجم بنزيل بنزوات لكل حقنة</strong>، أي ما يعادل 150 مجم / مل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيعطيك طبيبك أو ممرضتك كارسيڨور كحقنة بطيئة في العضل، واحدة في كل من الأرداف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي 500 ملجم فولفيسترانت (حقنتين 250 ملجم / 5 مل) تعطى مرة واحدة في الشهر، مع جرعة إضافية 500 ملجم بعد أسبوعين من الجرعة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضاً جانبية، على الرغم من عدم تعرض الجميع لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تحتاج إلى علاج طبي فوري إذا واجهت أيًا من الأعراض الجانبية التالية</strong></p><p dir="RTL">- تفاعلات الحساسية (فرط الحساسية)، بما في ذلك تورم الوجه والشفتين واللسان و / أو الحلق التي قد تكون علامات على تفاعلات تأقية</p><p dir="RTL">- الجلطات الدموية (زيادة خطر الإصابة بجلطات الدم) *</p><p dir="RTL">- التهاب الكبد (التهاب الكبد)</p><p dir="RTL">- فشل كبدي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي أو الممرضة إذا لاحظت أيًا من الأعراض الجانبية التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة جدًا </strong>(قد تظهر لدى أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">- تفاعلات موقع الحقن، مثل الألم و / أو الالتهاب</p><p dir="RTL">- مستويات غير طبيعية من إنزيمات الكبد (في فحوصات الدم) *</p><p dir="RTL">- الغثيان (الشعور بالغثيان)</p><p dir="RTL">- ضعف وتعب*</p><p dir="RTL">- آلام المفاصل والعضلات الهيكلية</p><p dir="RTL">- الهبات الساخنة</p><p dir="RTL">- الطفح الجلدي</p><p dir="RTL">- تفاعلات الحساسية (فرط الحساسية)، بما في ذلك انتفاخ الوجه والشفتين واللسان و / أو الحلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جميع الأعراض الجانبية الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة</strong> (قد تظهر لدى حتى 1 من كل 10 أشخاص)</p><p dir="RTL">- صداع الراس</p><p dir="RTL">- القيء أو الإسهال أو فقدان الشهية *</p><p dir="RTL">- التهابات المسالك البولية</p><p dir="RTL">- ألم في الظهر*</p><p dir="RTL">- زيادة نسبة البيليروبين (الصبغة الصفراوية التي ينتجها الكبد)</p><p dir="RTL">- الجلطات الدموية (زيادة خطر تجلط الدم) *</p><p dir="RTL">- انخفاض مستويات الصفيحات الدموية (قلة الصفيحات الدموية)</p><p dir="RTL">- نزيف مهبلي</p><p dir="RTL">- آلام أسفل الظهر مشعة للساق من جهة واحدة (عرق النسا)</p><p dir="RTL">- ضعف مفاجئ، تنميل، وخز، أو فقدان الحركة في ساقك، خاصة إذا كانت في جانب واحد فقط من جسمك، مشاكل مفاجئة في المشي أو التوازن (اعتلال الأعصاب الطرفية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة </strong>(قد تظهر لدى حتى 1 من كل 100 شخص)</p><p dir="RTL">- إفرازات مهبلية كثيفة بيضاء اللون وداء المبيضات (عدوى)</p><p dir="RTL">- كدمات ونزيف في مكان الحقن</p><p dir="RTL">- زيادة إنزيم جاما جي تي، وهو إنزيم كبدي يظهر في فحص الدم</p><p dir="RTL">- التهاب الكبد (التهاب الكبد)</p><p dir="RTL">- فشل كبدي</p><p dir="RTL">- التنميل والوخز والألم</p><p dir="RTL">- تفاعلات تأقية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">* يشمل الأعراض الجانبية التي لا يمكن تقييم الدور الدقيق لـ كارسيڨور بسبب المرض الأساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ونظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الكرتون أو ملصق الحقنة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخزين ونقل مبرد (2 - 8 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يكون الانحراف في درجات الحرارة خارج 2 إلى 8 درجات مئوية محدود. يتضمن ذلك تجنب التخزين في درجات حرارة تتجاوز 30 درجة مئوية، ولا تتجاوز فترة 28 يومًا حيث يكون متوسط درجة حرارة التخزين للمنتج أقل من 25 درجة مئوية (ولكن أعلى من 2 درجة مئوية إلى 8 درجات مئوية). بعد انحراف درجة الحرارة، يجب إعادة المنتج على الفور إلى ظروف التخزين الموصي بها (تخزين ونقل في الثلاجة من 2 إلى 8 درجات مئوية). يؤثر الانحراف في درجات الحرارة بشكل تراكمي على جودة المنتج ويجب عدم تجاوز الفترة الزمنية البالغة 28 يومًا على مدار فترة صلاحية كارسيڨور. لن يؤدي التعرض لدرجات حرارة أقل من 2 درجة مئوية إلى إتلاف المنتج بشرط عدم تخزينه في درجة حرارة أقل من 20- درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تخزين الحقنة المعبأة مسبقًا في العلبة الأصلية لحمايتها من الضوء.</p><p>&nbsp;</p><p dir="RTL">سيكون أخصائي الرعاية الصحية الخاص بك مسؤولاً عن التخزين الصحيح لـ كارسيڨور واستخدامه والتخلص منه</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يشكل هذا الدواء خطرًا على البيئة المائية. لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي فولفيسترانت. الكمية الإجمالية لكل حقنة كاملة 250 ملجم فولفيسترانت لكل 5 مل.</p><p dir="RTL">- الكمية في حجم الوحدة 50 ملجم فولفيسترانت لكل 1 مل.</p><p dir="RTL">- المكونات الأخرى (السواغات) هي الإيثانول (96٪) وكحول البنزيل (E1519) وبنزوات البنزيل وزيت الخروع المكرر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">كارسيڨور عبارة عن محلول لزج، عديم اللون إلى اللون الأصفر، في حقنة معبأة مسبقًا، تحتوي على 5 مل من محلول الحقن. يجب إعطاء حقنتين لتلقي الجرعة الشهرية الموصي بها 500 ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كارسيڨور على 3 عبوات تقديمية، عبوة تحتوي على حقنة زجاجية معبأة مسبقًا، عبوة تحتوي على حقنتين زجاجيتين معبأتين مسبقًا وعلبة تحتوي على 6 محاقن زجاجية معبأة مسبقًا. يتم أيضًا توفير إبرة واحدة أو اثنتين أو ستة إبر أمان (BD SafetyGlide) للاتصال بكل برميل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع:</strong></p><p dir="RTL">مختبرات فارمالان إس إيه</p><p dir="RTL">كالي لا فالينا إس إن إيديفيسيو 2</p><p dir="RTL">بوليجونو نافاتيجيرا الصناعية</p><p dir="RTL">24193 فيلاكويلامبر، ليون، إسبانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مالك الحقوق التسويقية:</strong></p><p dir="RTL">سبيماكو</p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CARCIVOR 250 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe of 5 ml contains 250 mg fulvestrant.
Total quantity per total volume 250 mg per 5 ml. 
Amount in unit volume 50 mg/ml.
 

Excipients with known effect (per 5 ml)
Ethanol 96% (alcohol), 500 mg
Benzyl alcohol (E1519), 500 mg
Benzyl benzoate, 750 mg

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled syringe

Clear, colorless to yellow, viscous solution, free from visible particles.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fulvestrant is indicated:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:</p><p>o&nbsp;&nbsp; not previously treated with endocrine therapy, or</p><p>o&nbsp;&nbsp; with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1).</p><p>&nbsp;</p><p>In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Adult females (including elderly)</em></p><p>The recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.</p><p>&nbsp;</p><p>When fulvestrant is used in combination with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.</p><p>&nbsp;</p><p>Prior to the start of treatment with the combination of fulvestrant plus palbociclib, and throughout its duration, pre/perimenopausal women should be treated with LHRH agonists according to local clinical practice.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Special population</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustments are recommended for patients with mild to moderate renal impairment (creatinine clearance &ge; 30 ml/min). Safety and efficacy have not been evaluated in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min), and, therefore, caution is recommended in these patients (see section 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustments are recommended for patients with mild to moderate hepatic impairment. However, as fulvestrant exposure may be increased, fulvestrant should be used with caution in these patients. There are no data in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of fulvestrant in children from birth to 18 years of age have not been established. Currently available data are described in sections 5.1 and 5.2, but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Fulvestrant should be administered as two consecutive 5 ml injections by slow intramuscular injection (1-2 minutes/injection), one in each buttock (gluteal area)</p><p>&nbsp;</p><p>Caution should be taken if injecting fulvestrant at the dorsogluteal site due to the proximity of the underlying sciatic nerve.</p><p>&nbsp;</p><p>For detailed instructions &nbsp;for administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                hypersensitivity to the active substance or to any of the excipients listed in section 6.1
pregnancy and lactation (see section 4.6)
severe hepatic impairment (see sections 4.4 and 5.2).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fulvestrant should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).</p><p>&nbsp;</p><p>Fulvestrant should be used with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min).</p><p>&nbsp;</p><p>Due to the intramuscular route of administration, fulvestrant should be used with caution if treating patients with bleeding diatheses, thrombocytopenia or those taking anticoagulant treatment.</p><p>&nbsp;</p><p>Thromboembolic events are commonly observed in women with advanced breast cancer and have been observed in clinical trials with fulvestrant (see section 4.8). This should be taken into consideration when prescribing fulvestrant to patients at risk.</p><p>&nbsp;</p><p>Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy have been reported with fulvestrant injection. Caution should be taken while administering fulvestrant at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>There are no long-term data on the effect of fulvestrant on bone. Due to the mechanism of action of fulvestrant, there is a potential risk of osteoporosis.</p><p>The efficacy and safety of fulvestrant (either as monotherapy or in combination with palbociclib) have not been studied in patients with critical visceral disease.</p><p>&nbsp;</p><p>When fulvestrant is combined with palbociclib, please also refer to the Summary of Product Characteristics of palbociclib.</p><p>&nbsp;</p><p><em>Interference with estradiol antibody assays</em></p><p>Due to the structural similarity of fulvestrant and estradiol, fulvestrant may interfere with antibody based-estradiol assays and may result in falsely increased levels of estradiol.</p><p>&nbsp;</p><p>Ethanol</p><p>This medicinal product contains 500 mg of alcohol (ethanol) in each injection which is equivalent to 100 mg/ ml (10% w/v). The amount in each injection of this medicine is equivalent to 13 ml beer or 5 ml wine.</p><p>&nbsp;</p><p>A dose of 500 mg of this medicine (two syringes) administered to an adult women weighing 70 kg would result in exposure to 14.3 mg / kg of ethanol which may cause a rise in blood alcohol concentration (BAC) of about 2.4 mg /100 ml&nbsp; (see Appendix I of report EMA/CHMP/43486/2018).</p><p>For comparison, for an adult drinking a glass of wine or 500 ml of beer, the BAC is likely to be about 50 mg/ 100 ml.</p><p>&nbsp;</p><p>Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects.</p><p>&nbsp;</p><p>Benzyl alcohol</p><p>This medicinal product contains benzyl alcohol as an excipient which may cause allergic reactions.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Fulvestrant is not recommended for use in children and adolescents as safety and efficacy have not been established in this group of patients (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A clinical interaction study with midazolam (substrate of CYP3A4) demonstrated that fulvestrant does not inhibit CYP3A4. Clinical interaction studies with rifampicin (inducer of CYP3A4) and ketoconazole (inhibitor of CYP3A4) showed no clinically relevant change in fulvestrant clearance.</p><p>Dose adjustment is therefore not necessary in patients who are receiving fulvestrant and CYP3A4 inhibitors or inducers concomitantly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Patients of childbearing potential should use effective contraception during treatment with CARCIVOR and for 2 years after the last dose.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Fulvestrant is contraindicated in pregnancy (see section 4.3). Fulvestrant has been shown to cross the placenta after single intramuscular doses in rat and rabbit. Studies in animals have shown reproductive toxicity including an increased incidence of foetal abnormalities and deaths (see section 5.3). If pregnancy occurs while taking fulvestrant, the patient must be informed of the potential hazard to the foetus and potential risk for loss of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Breast-feeding must be discontinued during treatment with fulvestrant. Fulvestrant is excreted in milk in lactating rats. It is not known whether fulvestrant is excreted in human milk. Considering the potential for serious adverse reactions due to fulvestrant in breast-fed infants, use during lactation is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effects of fulvestrant on fertility in humans has not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fulvestrant has no or negligible influence on the ability to drive or use machines. However, since asthenia has been reported very commonly with fulvestrant, caution should be observed by those patients who experience this adverse reaction when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p><em>Monotherapy</em></p><p>This section provides information based on all adverse reactions from clinical trials, post-marketing studies or spontaneous reports. In the pooled dataset of fulvestrant monotherapy, the most frequently reported adverse reactions are injection site reactions, asthenia, nausea, and increased hepatic enzymes (ALT, AST, ALP).</p><p>&nbsp;</p><p>In Table 1, the following frequency categories for adverse drug reactions (ADRs) were calculated based on the fulvestrant 500 mg treatment group in pooled safety analyses of studies that compared fulvestrant 500 mg with fulvestrant 250 mg [CONFIRM (Study D6997C00002), FINDER 1 (Study D6997C00004), FINDER 2 (Study D6997C00006), and NEWEST (Study D6997C00003) studies], or from FALCON (Study D699BC00001) alone that compared fulvestrant 500 mg with anastrozole 1 mg. Where frequencies differ between the pooled safety analysis and FALCON, the highest frequency is presented. The frequencies in the following table were based on all reported adverse drug reactions, regardless of the investigator assessment of causality. The median duration of fulvestrant 500 mg treatment across the pooled dataset (including the studies mentioned above plus FALCON) was 6.5 months.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency groupings are defined according to the following convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100). Within each frequency grouping adverse reactions are reported in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Drug Reactions reported in patients treated with fulvestrant monotherapy</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Adverse reactions by system organ class and frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urinary tract infections</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Reduced platelet counte</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypersensitivity reactionse</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anorexiaa</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hot flushese</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Venous thromboembolisma</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, diarrhoea</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Elevated hepatic enzymes (ALT, AST, ALP)a</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Elevated bilirubina</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatic failurec,f, hepatitisf,</p><p>elevated gamma-GTf</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rashe</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Joint and musculoskeletal paind</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Back paina</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast</p><p>disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vaginal haemorrhagee</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vaginal moniliasisf, leukorrheaf</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Astheniaa, injection site reactionsb</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neuropathy peripherale, sciaticae</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injection site haemorrhagef, injection site haematomaf,</p><p>neuralgiac,f</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes adverse drug reactions for which the exact contribution of fulvestrant cannot be assessed due to the underlying disease.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The term injection site reactions does not include the terms injection site haemorrhage and injection site haematoma, sciatica, neuralgia and neuropathy peripheral.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The event was not observed in major clinical studies (CONFIRM, FINDER 1, FINDER 2, NEWEST). The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate. This is calculated as 3/560 (where 560 is the number of patients in the major clinical studies), which equates to a frequency category of &lsquo;uncommon&rsquo;.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes: arthralgia, and less frequently musculoskeletal pain, myalgia and pain in extremity.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency category differs between pooled safety dataset and FALCON.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADR was not observed in FALCON.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>The descriptions included below are based on the safety analysis set of 228 patients who received at least one (1) dose of fulvestrant and 232 patients who received at least one (1) dose of anastrozole, respectively in the Phase 3 FALCON study.</p><p>&nbsp;</p><p><em>Joint and musculoskeletal pain</em></p><p>In the FALCON study, the number of patients who reported an adverse reaction of joint and musculoskeletal pain was 65 (31.2%) and 48 (24.1%) for fulvestrant and anastrozole arms, respectively. Of the 65 patients in the fulvestrant arm, 40% (26/65) of patients reported joint and musculoskeletal pain within the first month of treatment, and 66.2% (43/65) of patients within the first 3 months of treatment. No patients reported events that were CTCAE Grade &ge;3 or that required a dose reduction, dose interruption, or discontinued treatment due to these adverse reactions.</p><p>&nbsp;</p><p><em>Combination therapy with palbociclib</em></p><p>The overall safety profile of fulvestrant when used in combination with palbociclib is based on data from 517 patients with HR-positive, HER2-negative advanced or metastatic breast cancer in the randomised PALOMA3 study (see section 5.1). The most common (&ge;20%) adverse reactions of any grade reported in patients receiving fulvestrant in combination with palbociclib were neutropenia, leukopenia, infections, fatigue, nausea, anaemia, stomatitis, diarrhoea,&nbsp; thrombocytopenia and vomiting. The most common (&ge;2%) Grade &ge;3 adverse reactions were neutropenia, leukopenia, anaemia, infections, AST increased, thrombocytopenia, and fatigue.</p><p>&nbsp;</p><p>Table 2 reports the adverse reactions from PALOMA3.</p><p>Median duration of exposure to fulvestrant was 11.2 months in the fulvestrant + palbociclib arm and 4.8 months in the fulvestrant + placebo arm. Median duration of exposure to palbociclib in the fulvestrant + palbociclib arm was 10.8 months.</p><p>&nbsp;</p><p><strong>Table 2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions based on PALOMA3 Study (N=517)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>System Organ Class Frequency</strong></p><p><strong>Preferred Term</strong><strong>a</strong></p></td><td colspan="2"><p><strong>Fulvestrant + palbociclib (N=345)</strong></p></td><td colspan="2"><p><strong>Fulvestrant + placebo (N=172)</strong></p></td></tr><tr><td><p><strong>All Grades </strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Grade &ge;3 </strong></p><p><strong>n (%)</strong></p></td><td><p><strong>All Grades n (%)</strong></p></td><td><p><strong>Grade &ge;3 n (%)</strong></p></td></tr><tr><td colspan="5"><p><strong>Infections and infestations</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p><strong>System Organ Class</strong></p><p><strong>Frequency Preferred Term</strong><strong>a</strong></p></td><td colspan="2"><p><strong>Fulvestrant + palbociclib (N=345)</strong></p></td><td colspan="2"><p><strong>Fulvestrant + placebo (N=172)</strong></p></td></tr><tr><td><p><strong>All Grades n (%)</strong></p></td><td><p><strong>Grade &ge;3 n (%)</strong></p></td><td><p><strong>All Grades n (%)</strong></p></td><td><p><strong>Grade &ge;3 n (%)</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Infectionsb</p></td><td><p>188 (54.5)</p></td><td><p>19 (5.5)</p></td><td><p>60 (34.9)</p></td><td><p>6 (3.5)</p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Neutropeniac</p></td><td><p>290 (84.1)</p></td><td><p>240 (69.6)</p></td><td><p>6 (3.5)</p></td><td><p>0</p></td></tr><tr><td><p>Leukopeniad</p></td><td style="vertical-align:top"><p>207 (60.0)</p></td><td style="vertical-align:top"><p>132 (38.3)</p></td><td style="vertical-align:top"><p>9 (5.2)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td></tr><tr><td><p>Anaemiae</p></td><td style="vertical-align:top"><p>109 (31.6)</p></td><td style="vertical-align:top"><p>15 (4.3)</p></td><td style="vertical-align:top"><p>24 (14.0)</p></td><td style="vertical-align:top"><p>4 (2.3)</p></td></tr><tr><td><p>Thrombocytopeniaf</p></td><td><p>88 (25.5)</p></td><td><p>10 (2.9)</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p><em>Uncommon</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Febrile neutropenia</p></td><td><p>3 (0.9)</p></td><td><p>3 (0.9)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="5"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Decreased appetite</p></td><td style="vertical-align:top"><p>60 (17.4)</p></td><td style="vertical-align:top"><p>4 (1.2)</p></td><td style="vertical-align:top"><p>18 (10.5)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p><em>Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dysgeusia</p></td><td><p>27 (7.8)</p></td><td><p>0</p></td><td><p>6 (3.5)</p></td><td><p>0</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p><em>Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>25 (7.2)</p></td><td><p>0</p></td><td><p>2 (1.2)</p></td><td><p>0</p></td></tr><tr><td><p>Vision blurred</p></td><td style="vertical-align:top"><p>24 (7.0)</p></td><td><p>0</p></td><td><p>3 (1.7)</p></td><td><p>0</p></td></tr><tr><td><p>Dry eye</p></td><td style="vertical-align:top"><p>15 (4.3)</p></td><td><p>0</p></td><td><p>3 (1.7)</p></td><td><p>0</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p><em>Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Epistaxis</p></td><td><p>25 (7.2)</p><p>&nbsp;</p></td><td><p>0</p></td><td><p>4 (2.3)</p></td><td><p>0</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td style="vertical-align:top"><p>124 (35.9)</p></td><td style="vertical-align:top"><p>2 (0.6)</p></td><td style="vertical-align:top"><p>53 (30.8)</p></td><td><p>1 (0.6)</p></td></tr><tr><td><p>Stomatitisg</p></td><td style="vertical-align:top"><p>104 (30.1)</p></td><td style="vertical-align:top"><p>3 (0.9)</p></td><td style="vertical-align:top"><p>24 (14.0)</p></td><td><p>0</p></td></tr><tr><td><p>Diarrhoea</p></td><td style="vertical-align:top"><p>94 (27.2)</p></td><td><p>0</p></td><td style="vertical-align:top"><p>35 (20.3)</p></td><td><p>2 (1.2)</p></td></tr><tr><td><p>Vomiting</p></td><td style="vertical-align:top"><p>75 (21.7)</p></td><td><p>2 (0.6)</p></td><td style="vertical-align:top"><p>28 (16.3)</p></td><td><p>1 (0.6)</p></td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Alopecia</p></td><td style="vertical-align:top"><p>67 (19.4)</p></td><td><p>NA</p></td><td><p>11 (6.4)</p></td><td><p>NA</p></td></tr><tr><td><p>Rashh</p></td><td style="vertical-align:top"><p>63 (18.3)</p></td><td style="vertical-align:top"><p>3 (0.9)</p></td><td style="vertical-align:top"><p>10 (5.8)</p></td><td><p>0</p></td></tr><tr><td><p><em>Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dry skin</p></td><td><p>28 (8.1)</p></td><td><p>0</p></td><td><p>3 (1.7)</p></td><td><p>0</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p><em>Very common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fatigue</p></td><td style="vertical-align:top"><p>152 (44.1)</p></td><td style="vertical-align:top"><p>9 (2.6)</p></td><td style="vertical-align:top"><p>54 (31.4)</p></td><td style="vertical-align:top"><p>2 (1.2)</p></td></tr><tr><td><p>Pyrexia</p></td><td style="vertical-align:top"><p>47 (13.6)</p></td><td style="vertical-align:top"><p>1 (0.3)</p></td><td style="vertical-align:top"><p>10 (5.8)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td><p><em>Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Asthenia</p></td><td style="vertical-align:top"><p>27 (7.8)</p></td><td style="vertical-align:top"><p>1 (0.3)</p></td><td style="vertical-align:top"><p>13 (7.6)</p></td><td style="vertical-align:top"><p>2 (1.2)</p></td></tr><tr><td colspan="5"><p><strong>Investigations</strong></p></td></tr><tr><td><p><em>Very Common</em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>AST increased</p></td><td style="vertical-align:top"><p>40 (11.6)</p></td><td style="vertical-align:top"><p>11 (3.2)</p></td><td style="vertical-align:top"><p>13 (7.6)</p></td><td style="vertical-align:top"><p>4 (2.3)</p><p>&nbsp;</p></td></tr><tr><td><p><em>Common</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>ALT increased</p></td><td style="vertical-align:top"><p>30 (8.7)</p></td><td style="vertical-align:top"><p>7 (2.0)</p></td><td style="vertical-align:top"><p>10 (5.8)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td></tr></tbody></table><p>ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/n=number of patients; NA=Not applicable</p><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Terms (PTs) are listed according to MedDRA 17.1.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections includes all PTs that are part of the System Organ Class Infections and infestations.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia includes the following PTs: Neutropenia, Neutrophil count decreased.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukopenia includes the following PTs: Leukopenia, White blood cell count decreased.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia includes the following PTs: Anaemia, Haemoglobin decreased, Haematocrit decreased.</p><p>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia includes the following PTs: Thrombocytopenia, Platelet count decreased.</p><p>g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomatitis includes the following PTs: Aphthous stomatitis, Cheilitis, Glossitis, Glossodynia, Mouth ulceration, Mucosal inflammation, Oral pain, Oropharyngeal discomfort, Oropharyngeal pain, Stomatitis.</p><p>h&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes the following PTs: Rash, Rash maculo-papular, Rash pruritic, Rash erythematous, Rash papular, Dermatitis, Dermatitis acneiform, Toxic skin eruption.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Neutropenia</em></p><p>In patients receiving fulvestrant in combination with palbociclib in the PALOMA3 study, neutropenia of any grade was reported in &nbsp;290 (84.1%) patients, with Grade 3 neutropenia being reported in &nbsp;200 (58.0%) patients, and Grade 4 neutropenia being reported in 40 (11.6%)patients. In the fulvestrant + placebo arm (n=172), neutropenia of any grade was reported in 6 (3.5%) patients. There were no reports of Grade 3 and &nbsp;4 neutropenia in the fulvestrant + placebo arm.</p><p>&nbsp;</p><p>In patients receiving fulvestrant in combination with palbociclib, the median time to first episode of any grade neutropenia was 15 days (range: 13-512 days) and the median duration of Grade &ge;3 neutropenia was 16 days. Febrile neutropenia has been reported in 3 (0.9%) patients receiving fulvestrant in combination with palbociclib.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p><strong>For Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are isolated reports of overdose with fulvestrant in humans. If overdose occurs, symptomatic supportive treatment is recommended. Animal studies suggest that no effects other than those related directly or indirectly to anti-estrogenic activity were evident with higher doses of fulvestrant (see section 5.3).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Endocrine therapy, Anti-estrogens, ATC code: L02BA03</p><p><u>Mechanism of action and pharmacodynamic effects</u></p><p>Fulvestrant is a competitive estrogen receptor (ER) antagonist with an affinity comparable to estradiol.</p><p>Fulvestrant blocks the trophic actions of estrogens without any partial agonist (estrogen-like) activity. The mechanism of action is associated with down-regulation of estrogen receptor protein levels.</p><p>Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic estrogen agonist effects. It has also been shown that fulvestrant 500 mg downregulates ER and the proliferation marker Ki67, to a greater degree than fulvestrant 250 mg in breast tumours in postmenopausal neoadjuvant setting.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety in advanced breast cancer</u></p><p><em>Monotherapy</em></p><p>A phase3 clinical trial was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease. The study included 423 patients whose disease had recurred or progressed during anti-estrogen therapy (AE subgroup) and 313 patients whose disease had recurred or progressed during aromatase inhibitor therapy (AI subgroup). This trial compared the efficacy and safety of fulvestrant 500mg (n=362) with fulvestrant 250mg (n=374). Progression-free survival (PFS) was the primary endpoint; key secondary efficacy endpoints included objective response rate (ORR), clinical benefit rate (CBR) and overall survival (OS). Efficacy results for the CONFIRM study are summarized in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of results of the primary efficacy endpoint (PFS) and key secondary efficacy endpoints in the CONFIRM study</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Variable</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Type of estimate; treatment comparison</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Fulvestrant </strong><strong>500 mg (N=362)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Fulvestrant </strong><strong>250 mg (N=374)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Comparison between groups</strong></p><p><u>&nbsp;</u><u>&nbsp;&nbsp; <strong>(Fulvestrant 500 mg/Fulvestrant 250 mg) </strong></u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Hazard ratio</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td style="vertical-align:top"><p><strong>K-M</strong></p><p><strong>median in months; hazard ratio</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Patients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>0.80</p></td><td style="vertical-align:top"><p>0.68, 0.94</p></td><td style="vertical-align:top"><p>0.006</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AE subgroup (n=423)</strong></p></td><td style="vertical-align:top"><p>8.6</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>0.76</p></td><td style="vertical-align:top"><p>0.62, 0.94</p></td><td style="vertical-align:top"><p>0.013</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AI subgroup (n=313)</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>0.85</p></td><td style="vertical-align:top"><p>0.67, 1.08</p></td><td style="vertical-align:top"><p>0.195</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS</strong><strong>b</strong></p></td><td style="vertical-align:top"><p><strong>K-M</strong></p><p><strong>median in months; hazard ratio</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Patients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>26.4</p></td><td style="vertical-align:top"><p>22.3</p></td><td style="vertical-align:top"><p>0.81</p></td><td style="vertical-align:top"><p>0.69, 0.96</p></td><td style="vertical-align:top"><p>0.016c</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AE subgroup (n=423)</strong></p></td><td style="vertical-align:top"><p>30.6</p></td><td style="vertical-align:top"><p>23.9</p></td><td style="vertical-align:top"><p>0.79</p></td><td style="vertical-align:top"><p>0.63, 0.99</p></td><td style="vertical-align:top"><p>0.038c</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AI subgroup (n=313)</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>24.1</p></td><td style="vertical-align:top"><p>20.8</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>0.67, 1.11</p></td><td style="vertical-align:top"><p>0.241c</p></td></tr><tr><td style="vertical-align:top"><p><strong>Variable</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Type of estimate; treatment comparison</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Fulvestrant </strong><strong>500 mg (N=362)</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Fulvestrant </strong><strong>250 mg (N=374)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Comparison between groups</strong></p><p><u>&nbsp;</u><u>&nbsp;&nbsp; <strong>(Fulvestrant 500 mg/Fulvestrant 250 mg) </strong></u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Absolute difference in</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>ORR</strong><strong>d</strong></p></td><td style="vertical-align:top"><p><strong>% of patients with OR; absolute difference in</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Patients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13.8</p></td><td style="vertical-align:top"><p>14.6</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>-5.8, 6.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AE subgroup (n=296)</strong></p></td><td style="vertical-align:top"><p>18.1</p></td><td style="vertical-align:top"><p>19.1</p></td><td style="vertical-align:top"><p>-1.0</p></td><td style="vertical-align:top"><p>-8.2, 9.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AI subgroup (n=205)</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>-1.0</p></td><td style="vertical-align:top"><p>-5.5, 9.8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CBR</strong><strong>e</strong></p></td><td style="vertical-align:top"><p><strong>% of patients with CB; absolute difference in</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Patients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>45.6</p></td><td style="vertical-align:top"><p>39.6</p></td><td style="vertical-align:top"><p>6.0</p></td><td style="vertical-align:top"><p>-1.1, 13.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AE subgroup (n=423)</strong></p></td><td style="vertical-align:top"><p>52.4</p></td><td style="vertical-align:top"><p>45.1</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>-2.2, 16.6</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>-AI subgroup (n=313)</strong><strong>a</strong></p></td><td style="vertical-align:top"><p>36.2</p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>-6.1, 15.2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>aFulvestrant is indicated in patients whose disease had recurred or progressed on an anti-estrogen therapy. The results in the AI subgroup are inconclusive.</p><p>bOS is presented for the final survival analyses at 75% maturity.</p><p>cNominal p-value with no adjustments made for multiplicity between the initial overall survival analyses at 50% maturity and the updated survival analyses at 75% maturity.</p><p>d</p><p>ORR was assessed in patients who were evaluable for response at baseline (i.e., those with measurable disease</p><p>at baseline: 240 patients in the fulvestrant 500 mg group and 261 patients in the fulvestrant 250 mg group).</p><p>e</p><p>Patients with a best objective response of complete response, partial response or stable disease &ge;24 weeks.</p><p>PFS:Progression-free survival; ORR:Objective response rate; OR:Objective response; CBR:Clinical benefit rate; CB:Clinical benefit; OS:Overall survival; K-M:Kaplan-Meier; CI:Confidence interval; AI:Aromatase inhibitor; AE:Anti-estrogen.</p><p>&nbsp;</p><p>A Phase 3, randomised, double-blind, double-dummy, multicentre study of fulvestrant 500 mg versus anastrozole 1 mg was conducted in postmenopausal women with ER-positive and/or PgR-positive locally advanced or metastatic breast cancer who had not previously been treated with any hormonal therapy. A total of 462 patients were randomised 1:1 sequentially to receive either fulvestrant 500 mg or anastrozole 1 mg.</p><p>Randomisation was stratified by disease setting (locally advanced or metastatic), prior chemotherapy for advanced disease, and measurable disease.</p><p>&nbsp;</p><p>The primary efficacy endpoint of the study was investigator assessed progression-free survival (PFS) evaluated according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumours). Key secondary efficacy endpoints included overall survival (OS) and objective response rate (ORR).</p><p>&nbsp;</p><p>Patients enrolled in this study had a median age of 63 years (range 36-90). The majority of patients (87.0%) had metastatic disease at baseline. Fifty-five percent (55.0%) of patients had visceral metastasis at baseline. A total of 17.1% of patients received a prior chemotherapy regimen for advanced disease; 84.2% of patients had measurable disease.</p><p>&nbsp;</p><p>Consistent results were observed across the majority of pre-specified patient subgroups. For the subgroup of patients with disease limited to non-visceral metastasis (n=208), the HR was 0.592 (95% CI: 0.419, 0.837) for the fulvestrant arm compared to the anastrozole arm. For the subgroup of patients with visceral metastasis (n=254), the HR was 0.993 (95% CI: 0.740, 1.331) for the fulvestrant arm compared to the anastrozole arm. The efficacy results of the FALCON study are presented in Table 4 and Figure 1.</p><p>&nbsp;</p><p><strong>Table 4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of results of the primary efficacy endpoint (PFS) and key secondary efficacy endpoints (Investigator Assessment, Intent-To-Treat Population) ─ FALCON study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fulvestrant 500 mg</p><p>(N=230)</p></td><td style="vertical-align:top"><p>Anastrozole 1 mg</p><p>(N=232)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Progression-Free survival</p></td></tr><tr><td style="vertical-align:top"><p>Number of PFS Events (%)</p></td><td style="vertical-align:top"><p>143 (62.2%)</p></td><td style="vertical-align:top"><p>166 (71.6%)</p></td></tr><tr><td style="vertical-align:top"><p>PFS Hazard ratio (95% CI) and</p><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>HR 0.797 (0.637 &ndash; 0.999)</p><p>p = 0.0486</p></td></tr><tr><td style="vertical-align:top"><p>PFS Median [months (95% CI)]</p></td><td style="vertical-align:top"><p>16.6 (13.8, 21.0)</p></td><td style="vertical-align:top"><p>13.8 (12.0, 16.6)</p></td></tr><tr><td style="vertical-align:top"><p>Number of OS Events*</p></td><td style="vertical-align:top"><p>67 (29.1%)</p></td><td style="vertical-align:top"><p>75 (32.3%)</p></td></tr><tr><td style="vertical-align:top"><p>OS Hazard Ratio (95% CI) and</p><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>HR 0.875 (0.629 &ndash; 1.217)</p><p>p = 0.4277</p></td></tr><tr><td style="vertical-align:top"><p>ORR**</p></td><td style="vertical-align:top"><p>89 (46.1%)</p></td><td style="vertical-align:top"><p>88 (44.9%)</p></td></tr><tr><td style="vertical-align:top"><p>ORR Odds Ratio (95% CI) and</p><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>OR 1.074 (0.716 &ndash; 1.614) p = 0.7290</p></td></tr><tr><td style="vertical-align:top"><p>Median DoR (months)</p></td><td style="vertical-align:top"><p>20.0</p></td><td style="vertical-align:top"><p>13.2</p></td></tr><tr><td style="vertical-align:top"><p>CBR</p></td><td style="vertical-align:top"><p>180 (78.3%)</p></td><td style="vertical-align:top"><p>172 (74.1%)</p></td></tr><tr><td style="vertical-align:top"><p>CBR Odds Ratio (95% CI) and</p><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>OR 1.253 (0.815 &ndash; 1.932)</p><p>p = 0.3045</p></td></tr></tbody></table><p>*(31% maturity)-not final OS analysis</p><p>**for patients with measurable disease</p><p>&nbsp;</p><p><strong>Figure 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier Plot of Progression-Free Survival (Investigator Assessment, Intent-To-Treat Population) ─ FALCON Study</strong></p><p>&nbsp;</p><p><strong><img alt="" width="400" height="176" src="data:image/png;base64,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" /></strong></p><p>&nbsp;</p><p>Time from randomisation (months)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Cuadro_x0020_de_x0020_texto_x0020_8" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='width:348.75pt;height:21pt;visibility:visible;
 mso-wrap-style:square;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:17.35pt;line-height:6.95pt;
    mso-line-height-rule:exactly;tab-stops:28.35pt dashed 187.75pt'><span
    lang=EN-GB style='font-size:9.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-left:17.35pt;line-height:6.95pt;
    mso-line-height-rule:exactly;tab-stops:28.35pt dashed 187.75pt'><span
    lang=EN-GB style='font-size:9.0pt'>Treatment<span
    style='mso-spacerun:yes'>     </span>——— Fulvestrant 500<span
    style='letter-spacing:-.8pt'> </span>mg<span style='letter-spacing:-.05pt'>
    </span>(N=230)<span style='mso-tab-count:1'>       </span>Anastrozole 1 mg<span
    style='letter-spacing:-.05pt'> </span>(N=232)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="469" height="33" alt="Text Box: Treatment     ——— Fulvestrant 500 mg (N=230)	Anastrozole 1 mg (N=232)
" src="file:///C:/Users/P20190~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:348.75pt;
 height:21pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>Number of patients at risk</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>FUL500</p></td><td style="vertical-align:top"><p>230</p></td><td style="vertical-align:top"><p>187</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>124</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>81</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>ANAS1</p></td><td style="vertical-align:top"><p>232</p></td><td style="vertical-align:top"><p>194</p></td><td style="vertical-align:top"><p>162</p></td><td style="vertical-align:top"><p>139</p></td><td style="vertical-align:top"><p>120</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Two phase-3 clinical trials were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease. Seventy seven percent (77%) of the study population had estrogen receptor positive breast cancer. These trials compared the safety and efficacy of monthly administration of fulvestrant 250 mg versus the daily administration of 1 mg anastrozole (aromatase inhibitor). Overall, fulvestrant at the 250 mg monthly dose was at least as effective as anastrozole in terms of progression-free survival, objective response, and time to death. There were no statistically significant differences in any of these endpoints between the two treatment groups.</p><p>Progression-free survival was the primary endpoint. Combined analysis of both trials showed that 83% of patients who received fulvestrant progressed, compared with 85% of patients who received anastrozole. Combined analysis of both trials showed the hazard ratio of fulvestrant 250 mg to anastrozole for progression-free survival was 0.95 (95% CI 0.82 to 1.10). The objective response rate for fulvestrant 250 mg was 19.2% compared with 16.5% for anastrozole. The median time to death was 27.4 months for patients treated with fulvestrant and 27.6 months for patients treated with anastrozole. The hazard ratio of fulvestrant 250 mg to anastrozole for time to death was 1.01 (95% CI 0.86 to 1.19).</p><p>&nbsp;</p><p><em>Combination therapy with palbociclib</em></p><p>A Phase 3, international, randomised, double-blind, parallel-group, multicentre study of fulvestrant 500 mg plus palbociclib 125 mg versus fulvestrant 500 mg plus placebo was conducted in women with HR-positive, HER2-negative locally advanced breast cancer not amenable to resection or radiation therapy with curative intent or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after prior endocrine therapy in the (neo) adjuvant or metastatic setting.</p><p>&nbsp;</p><p>A total of 521 pre/peri- and postmenopausal women who had progressed on or within 12 months from completion of adjuvant endocrine therapy on or within 1 month from prior endocrine therapy for advanced disease, were randomised 2:1 to fulvestrant plus palbociclib or fulvestrant plus placebo and stratified by documented sensitivity to prior hormonal therapy, menopausal status at study entry (pre/peri- versus postmenopausal), and presence of visceral metastases. Pre/perimenopausal women received the LHRH agonist goserelin. Patients with advanced/metastatic, symptomatic, visceral spread, that were at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement), were not eligible for enrolment into the study.</p><p>&nbsp;</p><p>Patients continued to receive assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.</p><p>Crossover between treatment arms was not allowed.</p><p>&nbsp;</p><p>Patients were well matched for baseline demographics and prognostic characteristics between the fulvestrant plus palbociclib arm and the fulvestrant plus placebo arm. The median age of patients enrolled in this study was 57 years (range 29, 88). In each treatment arm the majority of patients were White, had documented sensitivity to prior hormonal therapy, and were postmenopausal.</p><p>Approximately 20% of patients were pre/perimenopausal. All patients had received prior systemic therapy and most patients in each treatment arm had received a previous chemotherapy regimen for their primary diagnosis. More than half (62%) had an ECOG PS of 0, 60% had visceral metastases, and 60% had received more than 1 prior hormonal regimen for their primary diagnosis.</p><p>&nbsp;</p><p>The primary endpoint of the study was investigator-assessed PFS evaluated according to RECIST 1.1. Supportive PFS analyses were based on an Independent Central Radiology Review. Secondary endpoints included OR, CBR, overall survival (OS), safety, and time-to-deterioration (TTD) in pain endpoint.</p><p>&nbsp;</p><p>The study met its primary endpoint of prolonging investigator-assessed PFS at the interim analysis conducted on 82% of the planned PFS events; the results crossed the pre-specified Haybittle-Peto efficacy boundary (&alpha;=0.00135), demonstrating a statistically significant prolongation in PFS and a clinically meaningful treatment effect. A more mature update of efficacy data is reported in Table 5.</p><p>&nbsp;</p><p>After a median follow-up time of 45 months, the final OS analysis was performed based on 310 events (60% of randomised patients). A 6.9-month difference in median OS in the palbociclib plus fulvestrant arm compared with the placebo plus fulvestrant arm was observed; this result was not statistically significant at the prespecified significance level of 0.0235(1-sided). In the placebo plus fulvestrant arm, 15.5% of randomised patients received palbociclib and other CDK inhibitors as post-progression subsequent treatments.</p><p>The results from the investigator-assessed PFS and final OS data from PALOMA3 study are presented in Table5. The relevant Kaplan-Meier plots are shown in Figures 2 and 3, respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results &ndash; PALOMA3 study (Investigator assessment, intent-to-treat population)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Updated Analysis</strong></p><p><strong>(23 October 2015 cut-off)</strong></p></td></tr><tr><td><p><strong>Fulvestrant plus palbociclib (N=347)</strong></p></td><td><p><strong>Fulvestrant plus placebo (N=174)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median [months (95% CI)]</p></td><td style="vertical-align:top"><p>11.2 (9.5, 12.9)</p></td><td style="vertical-align:top"><p>4.6 (3.5, 5.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI) and p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.497 (0.398, 0.620), p &lt;0.000001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Secondary end points*</strong></p></td></tr><tr><td style="vertical-align:top"><p>OR [% (95%CI)]</p></td><td style="vertical-align:top"><p>26.2 (21.7, 31.2)</p></td><td style="vertical-align:top"><p>13.8 (9.0, 19.8)</p></td></tr><tr><td style="vertical-align:top"><p>OR (measurable disease) [% (95%</p><p>CI)]</p></td><td style="vertical-align:top"><p>33.7 (28.1, 39.7)</p></td><td style="vertical-align:top"><p>17.4 (11.5, 24.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CBR [% (95% CI)]</p></td><td style="vertical-align:top"><p>68.0 (62.8, 72.9)</p></td><td style="vertical-align:top"><p>39.7 (32.3, 47.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Final overall survival (OS)</p><p>&nbsp;(13April 2018 cutoff)</p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>201 (57.9)</p></td><td style="vertical-align:top"><p>109 (62.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median [months (95% CI)]</p></td><td style="vertical-align:top"><p>34.9 (28.8, 40.0)</p></td><td style="vertical-align:top"><p>28.0 (23.6, 34.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI) and p-value<sup>&dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.814 (0.644, 1.029)</p><p>P=0.0429<sup>&dagger;</sup></p></td></tr></tbody></table><p>CBR=clinical benefit response; CI=confidence interval; N=number of patients; OR=objective response Secondary endpoint results are based on confirmed and unconfirmed responses according to RECIST 1.1.</p><p>* Not statistically significant.</p><p>&dagger;1-sided p-value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior endocrine therapy per randomisation.</p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Figure 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier plot of progression-free survival (investigator assessment, intent- to-treat population) &ndash; PALOMA3 study (23 October2015 cutoff)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><img alt="" width="510" height="359" src="data:image/png;base64,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" /></p><p>FUL=fulvestrant; PAL=palbociclib; PCB=placebo.</p><p>&nbsp;</p><p>A reduction in the risk of disease progression or death in the fulvestrant plus palbociclib arm was observed in all individual patient subgroups defined by stratification factors and baseline characteristics. This was evident for pre/perimenopausal women (HR of 0.46 [95% CI: 0.28, 0.75]) and postmenopausal women (HR of 0.52 [95% CI: 0.40, 0.66]) and patients with visceral site of metastatic disease (HR of 0.50 [95% CI: 0.38, 0.65]) and non-visceral site of metastatic disease (HR of 0.48 [95% CI: 0.33, 0.71]). Benefit was also observed regardless of lines of prior therapy in the metastatic setting, whether 0 (HR of 0.59 [95% CI: 0.37, 0.93]), 1 (HR of 0.46 [95% CI: 0.32, 0.64]), 2 (HR of 0.48 [95% CI: 0.30, 0.76]), or &ge;3 lines (HR of 0.59 [95% CI: 0.28, 1.22]).</p><p>&nbsp;</p><p>Figure 3. Kaplan-Meier plot of overall survival (intent-to-treat population) &ndash; PALOMA3 study (13 April 2018 cut off)</p><p><img alt="" width="483" height="333" src="data:image/png;base64,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" /></p><p>FUL= fulvestrant; PAL= palbociclib; PCB= placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p>Additional efficacy measures (OR and TTR) assessed in the sub-groups of patients with or without visceral disease are displayed in Table 6.</p><p>&nbsp;</p><p><strong>Table 6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results in visceral and non-visceral disease from PALOMA3 study (intent-to-treat population)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Visceral Disease</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Non-visceral Disease</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fulvestrant plus palbociclib</strong></p><p><strong>(N=206)</strong></p></td><td style="vertical-align:top"><p><strong>Fulvestrant plus placebo</strong></p><p><strong>(N=105)</strong></p></td><td style="vertical-align:top"><p><strong>Fulvestrant plus palbociclib</strong></p><p><strong>(N=141)</strong></p></td><td style="vertical-align:top"><p><strong>Fulvestrant plus placebo</strong></p><p><strong>(N=69)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OR [% (95%</strong></p></td><td style="vertical-align:top"><p>35.0</p></td><td style="vertical-align:top"><p>13.3</p></td><td style="vertical-align:top"><p>13.5</p></td><td style="vertical-align:top"><p>14.5</p></td></tr><tr><td style="vertical-align:top"><p><strong>CI)]</strong></p></td><td style="vertical-align:top"><p>(28.5, 41.9)</p></td><td style="vertical-align:top"><p>(7.5, 21.4)</p></td><td style="vertical-align:top"><p>(8.3, 20.2)</p></td><td style="vertical-align:top"><p>(7.2, 25.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>TTR*, Median</strong></p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>3.6</p></td></tr><tr><td style="vertical-align:top"><p><strong>[months</strong></p></td><td style="vertical-align:top"><p>(3.5, 16.7)</p></td><td style="vertical-align:top"><p>(3.5, 16.7)</p></td><td style="vertical-align:top"><p>(1.9, 13.7)</p></td><td style="vertical-align:top"><p>(3.4, 3.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>(range)]</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Response results based on confirmed and unconfirmed responses.</p><p>N=number of patients; CI=confidence interval; OR= objective response; TTR=time to first tumour response.</p><p>&nbsp;</p><p>Patient-reported symptoms were assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and its Breast Cancer Module (EORTC QLQ-BR23). A total of 335 patients in the fulvestrant plus palbociclib arm and 166 patients in the fulvestrant plus placebo arm completed the questionnaire at baseline and at least 1 post-baseline visit.</p><p>Time-to-Deterioration was pre-specified as time between baseline and first occurrence of &ge;10 points increase from baseline in pain symptom scores. Addition of palbociclib to fulvestrant resulted in a symptom benefit by significantly delaying Time-to-Deterioration in pain symptom compared with fulvestrant plus placebo (median 8.0 months versus 2.8 months; HR of 0.64 [95% CI: 0.49, 0.85]; p&lt;0.001.</p><p>&nbsp;</p><p><em>Effects on the postmenopausal endometrium</em></p><p>Preclinical data do not suggest a stimulatory effect of fulvestrant on the postmenopausal endometrium (see section 5.3). A 2-week study in healthy postmenopausal volunteers treated with 20 micrograms per day ethinylestradiol showed that pre-treatment with fulvestrant 250 mg resulted in significantly reduced stimulation of the postmenopausal endometrium, compared to pre-treatment with placebo, as judged by ultrasound measurement of endometrium thickness.</p><p>&nbsp;</p><p>Neoadjuvant treatment for up to 16 weeks in breast cancer patients treated with either fulvestrant 500 mg or fulvestrant 250 mg did not result in clinically significant changes in endometrial thickness, indicating a lack of agonist effect. There is no evidence of adverse endometrial effects in the breast cancer patients studied. No data are available regarding endometrial morphology.</p><p>&nbsp;</p><p>In two short-term studies (1 and 12 weeks) in premenopausal patients with benign gynaecologic disease, no significant differences in endometrial thickness were observed by ultrasound measurement between fulvestrant and placebo groups.</p><p>&nbsp;</p><p><em>Effects on bone</em></p><p>There are no long-term data on the effect of fulvestrant on bone. Neoadjuvant treatment for up to 16 weeks in breast cancer patients with either fulvestrant 500 mg or fulvestrant 250 mg did not result in clinically significant changes in serum bone-turnover markers.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Fulvestrant is not indicated for use in children. The European Medicines Agency has waived the obligation to submit the results of studies with fulvestrant in all subsets of the paediatric population in breast cancer (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>An open-label phase 2 study investigated the safety, efficacy and pharmacokinetics of fulvestrant in 30 girls aged 1 to 8 years with Progressive Precocious Puberty associated with McCune Albright Syndrome (MAS). The paediatric patients received 4 mg/kg monthly intramuscular dose of fulvestrant. This 12-month study investigated a range of MAS endpoints and showed a reduction in the frequency of vaginal bleeding and a reduction in the rate of bone age advancement. The steady-state trough concentrations of fulvestrant in children in this study were consistent with that in adults (see section 5.2). There were no new safety concerns arising from this small study, but 5-year data are yet not available.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After administration of fulvestrant long-acting intramuscular injection, fulvestrant is slowly absorbed and maximum plasma concentrations (C<sub>max</sub>) are reached after about 5 days. Administration of fulvestrant 500 mg regimen achieves exposure levels at, or close to, steady state within the first month of dosing (mean [CV]: AUC 475 [33.4%] ng.days/ml, C<sub>max</sub> 25.1 [35.3%] ng/ml, C<sub>min</sub> 16.3 [25.9%] ng/ml, respectively). At steady state, fulvestrant plasma concentrations are maintained within a relatively narrow range with up to an approximately 3-fold difference between maximum and trough concentrations. After intramuscular administration, the exposure is approximately dose-proportional in the dose range 50 to 500mg.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Fulvestrant is subject to extensive and rapid distribution. The large apparent volume of distribution at steady state (Vd<sub>ss</sub>) of approximately 3 to 5 l/kg suggests that distribution is largely extravascular.</p><p>Fulvestrant is highly (99%) bound to plasma proteins. Very low-density lipoprotein (VLDL), low density lipoprotein (LDL), and high-density lipoprotein (HDL) fractions are the major binding components. No interaction studies were conducted on competitive protein binding. The role of sex hormone-binding globulin (SHBG) has not been determined.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The metabolism of fulvestrant has not been fully evaluated but involves combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids. Identified metabolites (includes 17-ketone, sulphone, 3-sulphate, 3- and 17-glucuronide metabolites) are either less active or exhibit similar activity to fulvestrant in anti-estrogen models. Studies using human liver preparations and recombinant human enzymes indicate that CYP3A4 is the only P450 isoenzyme involved in the oxidation of fulvestrant; however, non-P450 routes appear to be more predominant in vivo. In vitro data suggest that fulvestrant does not inhibit CYP450 isoenzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Fulvestrant is eliminated mainly in metabolised form. The major route of excretion is via the faeces, with less than 1% being excreted in the urine. Fulvestrant has a high clearance, 11&plusmn;1.7 ml/min/kg, suggesting a high hepatic extraction ratio. The terminal half-life (t<sub>1/2</sub>) after intramuscular administration is governed by the absorption rate and was estimated to be 50 days.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>In a population pharmacokinetic analysis of data from phase 3studies, no difference in fulvestrant&#39;s pharmacokinetic profile was detected with regard to age (range 33 to 89 years), weight (40-127 kg) or race.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Mild to moderate impairment of renal function did not influence the pharmacokinetics of fulvestrant to any clinically relevant extent.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of fulvestrant has been evaluated in a single-dose clinical trial conducted in subjects with mild to moderate hepatic impairment (Child-Pugh class A and B). A high dose of a shorter duration intramuscular injection formulation was used. There was up to about 2.5-fold increase in AUC in women with hepatic impairment compared to healthy subjects. In patients administered fulvestrant, an increase in exposure of this magnitude is expected to be well tolerated. Women with severe hepatic impairment (Child-Pugh class C) were not evaluated.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of fulvestrant has been evaluated in a clinical trial conducted in 30 girls with Progressive Precocious Puberty associated with McCune Albright Syndrome (see section 5.1). The paediatric patients were aged 1 to 8 years and received 4 mg/kg monthly intramuscular dose of fulvestrant. The geometric mean (standard deviation) steady state trough concentration (Cmin,ss) and AUCss was 4.2 (0.9) ng/mL and 3680 (1020) ng*hr/mL, respectively. Although the data collected were limited, the steady-state trough concentrations of fulvestrant in children appear to be consistent with those in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The acute toxicity of fulvestrant is low.</p><p>&nbsp;</p><p>The reference medicinal product and other formulations of fulvestrant were well tolerated in animal species used in multiple dose studies. Local reactions, including myositis and granulomata at the injection site were attributed to the vehicle but the severity of myositis in rabbits increased with fulvestrant, compared to the saline control. In toxicity studies with multiple intramuscular doses of fulvestrant in rats and dogs, the anti- estrogenic activity of fulvestrant was responsible for most of the effects seen, particularly in the female reproductive system, but also in other organs sensitive to hormones in both sexes. Arteritis involving a range of different tissues was seen in some dogs after chronic (12 months) dosing.</p><p>&nbsp;</p><p>In dog studies following oral and intravenous administration, effects on the cardiovascular system (slight elevations of the S-T segment of the ECG [oral], and sinus arrest in one dog [intravenous]) were seen. These occurred at exposure levels higher than in patients (C<sub>max</sub> &gt;15 times) and are likely to be of limited significance for human safety at the clinical dose.</p><p>&nbsp;</p><p>Fulvestrant showed no genotoxic potential.</p><p>&nbsp;</p><p>Fulvestrant showed effects upon reproduction and embryo/foetal development consistent with its anti- estrogenic activity, at doses similar to the clinical dose. In rats, a reversible reduction in female fertility and embryonic survival, dystocia and an increased incidence of foetal abnormalities including tarsal flexure were observed. Rabbits given fulvestrant failed to maintain pregnancy. Increases in placental weight and post-implantation loss of foetuses were seen. There was an increased incidence of foetal variations in rabbits (backwards displacement of the pelvic girdle and 27 pre-sacral vertebrae).</p><p>&nbsp;</p><p>A two-year oncogenicity study in rats (intramuscular administration of fulvestrant) showed increased incidence of ovarian benign granulosa cell tumours in female rats at the high dose, 10 mg/rat/15 days and an increased incidence of testicular Leydig cell tumours in males. In a two-year mouse oncogenicity study (daily oral administration) there was an increased incidence of ovarian sex cord stromal tumours (both benign and malignant) at doses of 150 and 500 mg/kg/day. At the no-effect level for these findings, systemic exposure levels (AUC) were, in rats, approximately 1.5-fold the expected human exposure levels in females and 0.8-fold in males, and in mice, approximately 0.8-fold the expected human exposure levels in both males and females. Induction of such tumours is consistent with pharmacology-related endocrine feedback alterations in gonadotropin levels caused by anti-estrogens in cycling animals. Therefore these findings are not considered to be relevant to the use of fulvestrant in postmenopausal women with advanced breast cancer.</p><p>&nbsp;</p><p>Environmental Risk Assessment (ERA) Environmental risk assessment studies have shown that fulvestrant may have potential to cause adverse effects to the aquatic environment (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol (96%)</p><p>Benzyl alcohol (E1519)</p><p>Benzyl benzoate</p><p>Castor oil, refined</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Store and transport refrigerated (2&deg;C-8&deg;C).</em></p><p>&nbsp;</p><p>Temperature excursions outside 2&deg;C-8&deg;C should be limited. This includes avoiding storage at temperatures exceeding 30&deg;C, and not exceeding a 28 day period where the average storage temperature for the product is below 25&deg;C (but above 2&deg;C-8&deg;C). After temperature excursions, the product should be returned immediately to the recommended storage conditions (store and transport refrigerated 2&deg;C-8&deg;C). Temperature excursions have a cumulative effect on the product quality and the 28 daytime period must not be exceeded over the duration of the 2-year shelf life of fulvestrant (see section 6.3). Exposure to temperatures below 2&deg;C will not damage the product providing it is not stored below -20&deg;C.</p><p>&nbsp;</p><p>Store the pre-filled syringe in the original package in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pre-filled syringe presentation consists of:</p><p>&nbsp;</p><p>One clear type 1 glass pre-filled syringe with polystyrene plunger rod and elastomeric plunger stopper, fitted with a Plastic Rigid Tip cap, containing 5 ml fulvestrant solution for injection.</p><p>A safety needle (BD SafetyGlide) for connection to the barrel is also provided.</p><p>Or</p><p>Two clear type 1 glass pre-filled syringes with polystyrene plunger rod and elastomeric plunger stopper, fitted with a Plastic Rigid Tip cap, each containing 5 ml fulvestrant solution for injection. Two safety needles (BD SafetyGlide) for connection to each barrel are also provided.</p><p>&nbsp;</p><p>Or</p><p>Six clear type 1 glass pre-filled syringes with polystyrene plunger rod and elastomeric plunger stopper, fitted with a Plastic Rigid Tip cap, each containing 5 ml fulvestrant solution for injection. Six safety needles (BD SafetyGlide) for connection to each barrel are also provided.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Instructions for administration</u></p><p>&nbsp;</p><p>Administer the injection according to the local guidelines for performing large volume intramuscular injections.</p><p>&nbsp;</p><p>NOTE: Due to the proximity of the underlying sciatic nerve, caution should be taken if administering fulvestrant at the dorsogluteal injection site (see section 4.4).</p><p>&nbsp;</p><p>Warning - Do not autoclave safety needle (BD SafetyglideTM&nbsp; Safety Hypodermic Needle) before use. Hands must remain behind the needle at all times during use and disposal.</p><p>&nbsp;</p><p>For each of the two syringes:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove glass syringe barrel from tray and check that it is not damaged.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel open the safety needle (SafetyGlide) outer packaging.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral solutions must be inspected visually for particulate matter and discolouration prior to administration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold the syringe upright on the ribbed part (C). With the other hand, take hold of the cap (A) and carefully twist the plastic rigid tip cap in anticlockwise direction. (see Figure 1):</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="227" height="218" vspace="0" hspace="0" border="0" style="width:227px;height:218px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Figure 1</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the cap (A) in a straight upward direction. To maintain sterility do not touch the syringe tip (B) (see Figure 2).</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="227" height="231" vspace="0" hspace="0" border="0" style="width:227px;height:231px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Figure 2</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attach the safety needle to the Luer-Lok and twist until firmly seated (see Figure 3).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check that the needle is locked to the Luer connector before moving out of the vertical plane.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pull shield straight off needle to avoid damaging needle point.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transport filled syringe to point of administration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove needle sheath.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Expel excess gas from the syringe.</p><p><img src="data:image/png;base64,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" alt="" width="192" height="248" vspace="0" hspace="0" border="0" style="width:192px;height:248px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Figure 3</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer intramuscularly slowly (1-2 minutes/injection) into the buttock (gluteal area). For user convenience, the needle bevel- up position is oriented to the lever arm (see Figure 4).</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="195" height="129" vspace="0" hspace="0" border="0" style="width:195px;height:129px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Figure 4</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After injection, immediately apply a single-finger stroke to the activation assisted lever arm to activate the shielding mechanism (see Figure 5).</p><p>&nbsp;</p><p>NOTE: Activate away from self and others. Listen for click and visually confirm needle tip is fully covered.</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="161" height="215" vspace="0" hspace="0" border="0" style="width:161px;height:215px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Figure 5</p><p>&nbsp;</p><p><u>Disposal</u></p><p>Pre-filled syringes are for single use <strong>only</strong>.</p><p>This medicine may pose a risk to the aquatic environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements (see section 5.3).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Manufacturer:
	Laboratorios Farmalan SA
	Calle La Vallina, s n Edificio 2 
	Poligono Industrial Navatejera,
	24193 Villaquilambre Leon, Spain
	

	Marketing Authorization Holder:
	SPIMACO
	Al-Qassim Pharmaceutical Plant
	Saudi Arabia


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>